Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232267 · ClinicalTrials.gov registry record
Analysis of Sleep Study Data to Assess Depressive Burden
A clinical trial of Mood Disorders and Sleep Disorder, sponsored by Medibio Limited.
- Completed
- Registry status
- 329
- Enrollment target
- 5
- Study locations
NCT04232267: Completed study of Mood Disorders and Sleep Disorder, sponsored by Medibio Limited.
NCT04232267 is a study of Mood Disorders and Sleep Disorder that has completed, run by Medibio Limited. The registered enrollment target is 329 participants, below the 929-participant average among 39 other Mood Disorders trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04232267, a study of Mood Disorders and Sleep Disorder, has completed, sponsored by Medibio Limited.
- COMPLETED
- Registry status
- 329 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively reported by the subject with the Beck Depression Inventory - II (BDI-II).
Primary Outcome
Utilize PSG data and BDI-II to determine clinical depressive burden.
Conditions Studied
Interventions
- DEVICE MEB-001
Study Locations (5)
Ohio
- Ohio Sleep Solutions - Columbus
- Ohio Sleep Solutions - Grove City
- Ohio Sleep Solutions - Hilliard
Minnesota
- Restore Sleep Clinic - Blaine
- Lakeland Sleep and CPAP - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2022-03-01 |
What the finished NCT04232267 record still lists
NCT04232267 is an observational study that tracks outcomes without assigning an intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, below the 929-participant average among 39 other Mood Disorders trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Mood Disorders appearing as the primary indexed condition, and to 1 intervention - of which MEB-001 is the first listed.
NCT04232267 lists 5 locations in 2 states (Ohio, Minnesota).
Frequently Asked Questions
What is clinical trial NCT04232267 about?
NCT04232267 is a clinical study titled "Analysis of Sleep Study Data to Assess Depressive Burden". This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively r...
What is the current status of trial NCT04232267?
This trial is currently completed. The enrollment target is 329 participants. The study started on 2020-01-13. Estimated completion is 2022-03-01.
What conditions does trial NCT04232267 study?
This clinical trial studies the following conditions: Mood Disorders, Sleep Disorder, Depressive; Behavioral Disorder.
What interventions are being tested in trial NCT04232267?
The interventions under investigation include: MEB-001 (DEVICE).
Who is sponsoring clinical trial NCT04232267?
This trial is sponsored by Medibio Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04232267 being conducted?
This trial has 5 study locations across Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04232267's enrollment target sits among peer trials
329 11th of 39 higher than 29 of 39 other Mood Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mood Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Clinical Validation of Samsung Smartwatch
RECRUITING
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Resilience in Adolescent Development
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI